Free Trial

Akari Therapeutics (AKTX) Competitors

Akari Therapeutics logo
$1.16 -0.01 (-0.86%)
Closing price 03:59 PM Eastern
Extended Trading
$1.16 +0.00 (+0.43%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AKTX vs. FATE, KYTX, BDTX, VXRT, LXEO, LYEL, BYSI, NMRA, NKTX, and FTLF

Should you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Vaxart (VXRT), Lexeo Therapeutics (LXEO), Lyell Immunopharma (LYEL), BeyondSpring (BYSI), Neumora Therapeutics (NMRA), Nkarta (NKTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry.

Akari Therapeutics vs. Its Competitors

Akari Therapeutics (NASDAQ:AKTX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Akari Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -213.59% -65.60%
Fate Therapeutics -1,318.93%-47.17%-34.60%

Akari Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.

In the previous week, Akari Therapeutics and Akari Therapeutics both had 2 articles in the media. Akari Therapeutics' average media sentiment score of 0.82 beat Fate Therapeutics' score of 0.65 indicating that Akari Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fate Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Akari Therapeutics has higher earnings, but lower revenue than Fate Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$19.79MN/AN/A
Fate Therapeutics$13.63M9.42-$186.26M-$1.49-0.75

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 38.1% of Akari Therapeutics shares are held by company insiders. Comparatively, 5.5% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Fate Therapeutics has a consensus price target of $3.83, indicating a potential upside of 242.26%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Fate Therapeutics
0 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.13

Summary

Fate Therapeutics beats Akari Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Akari Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKTX vs. The Competition

MetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$37.17M$2.90B$5.49B$8.93B
Dividend YieldN/A2.69%5.38%4.13%
P/E RatioN/A21.3126.2119.90
Price / SalesN/A241.40405.84161.31
Price / CashN/A41.8936.4957.06
Price / Book1.387.518.055.38
Net Income-$19.79M-$55.05M$3.15B$248.50M
7 Day Performance-0.43%2.45%1.85%2.97%
1 Month Performance-18.37%7.33%4.81%6.02%
1 Year Performance-62.74%5.38%34.86%20.39%

Akari Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKTX
Akari Therapeutics
1.609 of 5 stars
$1.16
-0.9%
N/A-64.2%$37.17MN/A0.009News Coverage
FATE
Fate Therapeutics
4.0881 of 5 stars
$1.14
-4.2%
$3.83
+236.3%
-65.0%$136.38M$13.63M-0.77550Gap Down
KYTX
Kyverna Therapeutics
1.5918 of 5 stars
$3.22
+4.9%
$18.50
+474.5%
-64.5%$132.68M$7.03M-0.9596
BDTX
Black Diamond Therapeutics
3.2599 of 5 stars
$2.27
-2.6%
$14.60
+543.2%
-47.2%$132.49MN/A37.8390Positive News
Analyst Upgrade
VXRT
Vaxart
2.3402 of 5 stars
$0.56
-3.4%
$3.00
+435.3%
-33.2%$132.42M$28.70M-2.08120Positive News
Gap Down
LXEO
Lexeo Therapeutics
2.4959 of 5 stars
$3.96
+1.3%
$16.60
+319.2%
-73.0%$129.80M$650K-1.2058News Coverage
LYEL
Lyell Immunopharma
3.3142 of 5 stars
$8.99
+3.5%
$20.00
+122.5%
-70.2%$128.68M$60K-0.36270
BYSI
BeyondSpring
N/A$2.74
-13.6%
N/A-2.0%$127.80M$1.75M0.0080High Trading Volume
NMRA
Neumora Therapeutics
2.5663 of 5 stars
$0.75
-5.1%
$9.29
+1,144.7%
-92.0%$127.08MN/A-0.46108News Coverage
Positive News
NKTX
Nkarta
2.2473 of 5 stars
$1.75
-1.4%
$14.33
+721.4%
-70.8%$125.60MN/A-1.16140News Coverage
FTLF
FitLife Brands
4.3806 of 5 stars
$12.99
-2.5%
$20.50
+57.8%
-14.3%$125.09M$64.47M15.4620

Related Companies and Tools


This page (NASDAQ:AKTX) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners